PPT-Fractionated BDD 2 MGUS & Myeloma

Presenter Disclosure Faculty Mark Kristjanson Relationships with commercial interests none Mitigating Potential Bias Not Applicable Learning Objectives List the indications for SPEP amp FLC. Dr. Andrew Chantry. Senior Clinical Lecturer and Honorary Consultant in . Haematology. University of Sheffield and Sheffield Teaching Hospitals NHS Foundation Trust. UKMF Autumn Educational Day ‘The evolving management of multiple myeloma and related plasma cell disorders’. Ready for Prime Time?. DANA-FARBER . CANCER INSTITUTE. Nikhil C. Munshi, MD . Professor of Medicine . Harvard Medical School. Boston VA Healthcare System. Director . Basic and Correlative Sciences. Dana-Farber Cancer . Dr Matthew Jenner. Consultant Haematologist. Southampton General Hospital . UK Myeloma Forum Autumn Day. 12 November 2014. Introduction. Why define high risk myeloma?. 3. Patient expectations. Outcomes vary widely between different patients. –. . Part II. CS . 6340. 1. Unification vs. Inclusion. Earlier scalable pointer analysis was context-insensitive unification-based [. Steensgaard. ’96]. Pointers are . either un-aliased . or point . Paul Moss. Birmingham, UK. Outline. Introduction to immunotherapy. Immunotherapy in the setting of Myeloma . Cellular therapy. Future application. History of Cancer Therapy. Surgery. 1000s of years. Radiotherapy. Mike Chapman. University of Cambridge Department of Haematology. Novel agents have improved survival. What is a biomarker?. “A characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention”. Program Goals. Defining Multiple Myeloma. Case 1. Diagnostic Criteria. Multiple Myeloma Requiring Therapy. Cytogenetic Risk Features. Case 1 (cont). Newly Diagnosed Multiple Myeloma. NCCN. ®. . Therapy for Transplant-Eligible Patients. Part I: Smoldering Multiple Myeloma . and . Induction Therapy for Patients with Newly Diagnosed Multiple Myeloma . Moderator: . Sagar. . Lonial. , MD. Panelists: . Jonathan Kaufman, MD and Ajay . Nooka. cyclin. and PI3k pathways. UKMF Spring meeting 2015. Kwee Yong, UCL Cancer Institute. Not one, but many myelomas. Dysregulation. of D-type . cyclin. in multiple myeloma. Early oncogenic events . dysregulate. Professor Mark Drayson, University of Birmingham. 13. th. March 2019. Distinguishing myeloma from MGUS by m-protein and serum free light chain results alone. M. yeloma . is the worst cancer for delayed diagnosis . Aric Hall, MD. Assistant Professor – UW Health. Objectives . To discuss pathophysiology of plasma cell disorders. To define and describe the asymptomatic plasma cell dyscrasias. To discuss prognosis. Inventory Management Platform. April 2013 . Who we are…. p. . 2. “We are passionate about changing retail for the better.. We build products that help shoppers shop and sellers sell.” . Some of our properties…. Grace B. Athas, Ph.D. . MLS. Department of pathology, LSUHSC. CLPC Spring seminar series, 2018 . Learning objectives. Review pathophysiology and lab diagnosis of plasma cell neoplasms with a focus on Multiple Myeloma. [Hospital]. [date]. Myeloma: Symptoms to diagnosis . Can we do better?.